top of page

Partner with Rubik
Oncology Collaboration Opportunities

Rubik Therapeutics offers modality-ready cancer targets for licensing or collaboration.   Discover how we partner with biopharma and platform companies. 

Working Together

Partnership Experience

  • Rubik has completed multiple cancer target deals in the past 18 months. 

  • Radioligand and intracellular

Collaboration Models

  • Target Licensing

  • Co-development

  • Discovery Partnerships

Available Assets

  • Highly selective targets tuned to ADC, Radioligand, CAR-T and intracellular targets

  • Binder options: antibodies, peptides, protein

  • Expression validation across tumor and normal tissue. 

© 2023 by Rubik Therapeutics. All rights reserved.

bottom of page